|USA Edition||Today Is Tuesday December 10th, 2013|
|We know now that Government by organized money is just as dangerous as Government by organized mob - Franklin Delano Roosevelt|
|DOD Assessment: U.S. Forces Have Crushed Al-Qaida||Browse All Content||Jennifer Segrest Arrested By U.S. Marshals On Child Molestation Charges In Georgia|
|Previous In Section||Browse
Justice Department Section
|Next In Section|
Pharmaceutical companies that participate in Medicaid must accurately report drug prices and pay their fair share of rebates to the federal and statement governments. Settlements like this one help maintain important programs on which so many depend for needed health care.
Tony West, Assistant Attorney General
Dava Pharmaceuticals To Pay U.S. $11 Million To Settle False Claims Act Allegations
Dava Pharmaceuticals Inc. has agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations, the Justice Department announced today.
February 8, 2012
The settlement resolves allegations that between Oct. 1, 2005 and Sept. 30, 2009, Dava and its corporate predecessors knowingly underpaid their rebate obligations under the Medicaid Prescription Drug Rebate Program. Under that program, participating drug companies are required to pay quarterly rebates to state Medicaid programs based, in part, on whether a drug is a “generic” or “branded” product and the difference between what the health care program paid for the drug and prices paid by other purchasers.
In order to reduce its Medicaid rebate obligation, Dava incorrectly treated its version of the drugs cefdinir, clarithromycin and methotrexate as “generic” drugs rather than “branded” products, thereby lowering the overall percentage rebate payable to Medicaid. In addition, Dava further reduced its Medicaid rebate obligations by incorrectly calculating average manufacturer prices for its versions of the drugs cefdinir, clarithromycin, methotrexate and rheumatrex. As a result, Dava underpaid drug rebates to the Medicaid program and overcharged certain public health service entities for these products.
“Pharmaceutical companies that participate in Medicaid must accurately report drug prices and pay their fair share of rebates to the federal and statement governments,” said Tony West, Assistant Attorney General for the Civil Division of the Department of Justice. “Settlements like this one help maintain important programs on which so many depend for needed health care.”
The federal government’s portion of the settlement is approximately $5.7 million. Dava will also pay over $5 million to the Medicaid participating states and approximately $200,000 to certain public health services entities who paid inflated prices for the drugs at issue.
The settlement resolves a lawsuit filed in federal court in the District of Maryland under the qui tam, or whistleblower, provisions of the False Claims Act, which allow private citizens to bring civil actions on behalf of the United States and share in any recovery. As part of today’s resolution, the whistleblower – Jim Conrad – will receive 15 percent of the settlement proceeds.
This resolution is part of the government’s emphasis on combating health care fraud and another success for the Health Care Fraud Prevention and Enforcement Action Team (HEAT) initiative, which was announced by Attorney General Eric Holder and Kathleen Sebelius, Secretary of the Department of Health and Human Services in May 2009. The partnership between the two departments has focused efforts to reduce and prevent Medicare and Medicaid fraud through enhanced cooperation. One of the most powerful tools in that effort is the False Claims Act, which the Justice Department has used to recover more than $6.6 billion since January 2009 in cases involving fraud against federal health care programs. The Justice Department’s total recoveries in False Claims Act cases since January 2009 are over $8.8 billion.
The investigation was handled by the Justice Department’s Civil Division, the U.S. Attorney’s Office for the District of Maryland, the Department of Health and Human Services’ Office of Inspector General and Office of Counsel to the Inspector General, and the National Association of Medicaid Fraud Control Units.
|Governance & Privacy|
|International Monetary Fund||Federal Reserve||European Central Bank||United Nations|
|Justice Department||State Department||Defense Department||Treasury Department||Transportation Department||Homeland Security Department||Commerce Department||Energy Department||Interior Department||Securities & Exchange Commission||Federal Trade Commission||National Institutes Of Health|
Seeing Is Believing
Thinking & AnalysisCritical Thinking
U.S. MilitaryAir Force
Legal & CourtsFederal Courts
Judgments & Opinions
House Of Representatives
Library Of Congress
United States Senate
HumanitiesBusiness Of Life
The Human Condition
OpinionCivility & Values
Conversations With America
Food For Thought
Contact UsOffer A Comment
Letters To The Editor
About UsAsk Newsroom
Errors & Omissions
Standards & PracticesCode Of Ethics
Government, Institutional And Commercial News Standards
Newsroom Magazine Founding Contributors
Newsroom Magazine USA Edition | Copyright © 2006 - 2013 Newsroom Publishing, Inc. | All Rights Reserved
Newsroom Magazine Is Powered By YourColo Data Power Station Servers
Newsroom Publishing Content Access Monitored By Tracker CMS Metrics
Data Power Station Load When This Page Was Delivered Was 10.83 % Of Allocated Power Station Capacity
SQL Queries For This Page = 165
Page Generation Time = 1.1 seconds